Studies on lixisenatide and liraglutide treatments in T2DM revealed that the effect of GLP-1 agonists is on both the production and clearance of ApoB48, hence lowering postprandial TG [6]. This evidence concerns the gene APOB and type 2 diabetes mellitus.